Literature DB >> 3009442

Characterization of Haemophilus influenzae nucleotide pyrophosphatase. An enzyme of critical importance for growth of the organism.

D W Kahn, B M Anderson.   

Abstract

A nucleotide pyrophosphatase isolated from Haemophilus influenzae was purified to electrophoretic homogeneity and characterized with respect to molecular weight, substrate specificity, pH profile, thermal stability, functional group involvement, and effectiveness of selective inhibition. The enzyme catalyzes the hydrolysis of NAD to NMN and AMP and appears located appropriately to facilitate the internalization of NAD needed to satisfy the V-factor growth requirement of the organism. In the processing of NAD and structurally related substrates, the enzyme exhibited negative cooperativity. Structural alterations in the purine moiety of these dinucleotide substrates had pronounced effects on the negative cooperativity of the enzyme. AMP, ADP, and several related nucleotides were observed to be effective substrate-competitive inhibitors of the enzyme. Several of the dinucleotides serving as substrates for the nucleotide pyrophosphatase were evaluated with respect to substituting for NAD in supporting growth of the organism. AMP and ADP inhibited growth of the organism when NAD served as V-factor, and this inhibition correlated well with the inhibitory effects of these nucleotides on the purified nucleotide pyrophosphatase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009442

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  A superfamily of metalloenzymes unifies phosphopentomutase and cofactor-independent phosphoglycerate mutase with alkaline phosphatases and sulfatases.

Authors:  M Y Galperin; A Bairoch; E V Koonin
Journal:  Protein Sci       Date:  1998-08       Impact factor: 6.725

2.  Nicotinamide ribosyl uptake mutants in Haemophilus influenzae.

Authors:  Mark Herbert; Elizabeta Sauer; Graeme Smethurst; Anita Kraiss; Anna-Karina Hilpert; Joachim Reidl
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

3.  Coupling of NAD+ biosynthesis and nicotinamide ribosyl transport: characterization of NadR ribonucleotide kinase mutants of Haemophilus influenzae.

Authors:  Melisa Merdanovic; Elizabeta Sauer; Joachim Reidl
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

Review 4.  NAD+ utilization in Pasteurellaceae: simplification of a complex pathway.

Authors:  Gabriele Gerlach; Joachim Reidl
Journal:  J Bacteriol       Date:  2006-10       Impact factor: 3.490

5.  NadN and e (P4) are essential for utilization of NAD and nicotinamide mononucleotide but not nicotinamide riboside in Haemophilus influenzae.

Authors:  G Kemmer; T J Reilly; J Schmidt-Brauns; G W Zlotnik; B A Green; M J Fiske; M Herbert; A Kraiss; S Schlör; A Smith; J Reidl
Journal:  J Bacteriol       Date:  2001-07       Impact factor: 3.490

6.  PnuC and the utilization of the nicotinamide riboside analog 3-aminopyridine in Haemophilus influenzae.

Authors:  Elizabeta Sauer; Melisa Merdanovic; Anne Price Mortimer; Gerhard Bringmann; Joachim Reidl
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

7.  In vitro evaluation of nicotinamide riboside analogs against Haemophilus influenzae.

Authors:  C P Godek; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

8.  Permeability of Rickettsia prowazekii to NAD.

Authors:  W H Atkinson; H H Winkler
Journal:  J Bacteriol       Date:  1989-02       Impact factor: 3.490

9.  Studies on the effect of NAD(H) on nitrogenase activity in Rhodospirillum rubrum.

Authors:  A Soliman; S Nordlund
Journal:  Arch Microbiol       Date:  1992       Impact factor: 2.552

10.  Characterization of riboflavin (vitamin B2) transport proteins from Bacillus subtilis and Corynebacterium glutamicum.

Authors:  Christian Vogl; Simon Grill; Oliver Schilling; Jörg Stülke; Matthias Mack; Jürgen Stolz
Journal:  J Bacteriol       Date:  2007-08-10       Impact factor: 3.490

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.